Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbaclofen for Social Function in Children With Fragile X Syndrome
NCT01325220Phase 3Completed
- Sponsor
- Seaside Therapeutics
- Start
- Jun 2011
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of arbaclofen in Fragile X syndrome (FXS), sponsored by Seaside Therapeutics. Started Jun 2011; status: completed.
02
Drugs
arbaclofen
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT01325220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01325220.